Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear

• Published in: Proceedings of the National Academy of Sciences - PNAS 2020-05, Vol.117 (21), p.11781-11787
• Main Authors: Kreuder, Ann-Kathrin, Scheele, Dirk, Schultz, Johannes, Hennig, Juergen, Marsh, Nina, Dellert, Torge, Ettinger, Ulrich, Philipsen, Alexandra, Babasiz, Mari, Herscheid, Angela, Remmersmann, Laura, Stirnberg, Ruediger, Stöcker, Tony, Hurlemann, René
• Format: Article
• Language: English
• Subjects: Amygdala; Anxiety; Anxiolytics; Benzodiazepines; Biological Sciences; Circuits; Clinical trials; Cortex (parietal); Coupling; Drug therapy; Fear; Functional magnetic resonance imaging; Inhibition (psychology); Lorazepam; Neural networks; Oxytocin; Prefrontal cortex; Psychotropic drugs; Side effects
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1920147117

Benzodiazepines (BZDs) represent the gold standard of anxiolytic pharmacotherapy; however, their clinical benefit is limited by side effects and addictive potential. Consequently, there is an urgent need to develop novel and safe anxiolytics. The peptide hormone oxytocin (OXT) exhibits anxiolytic-like properties in animals and humans, but whether OXT and BZDs share similar effects on the neural circuitry of fear is unclear. Therefore, the rationale of this ultra-high-field functional MRI (fMRI) study was to test OXT against the clinical comparator lorazepam (LZP) with regard to their neuromodulatory effects on local and network responses to fear-related stimuli. One hundred twenty-eight healthy male participants volunteered in this randomized double-blind, placebocontrolled, between-group study. Before scanning using an emotional face-matching paradigm, participants were randomly administered a single dose of OXT (24 IU), LZP (1 mg), or placebo. On the behavioral level, LZP, but not OXT, caused mild sedation, as evidenced by a 19% increase in reaction times. On the neural level, both OXT and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA). In contrast, they had different effects on intra-amygdalar connectivity; OXT strengthened the coupling between the cmA and basolateral amygdala, whereas LZP increased the interplay between the cmA and superficial amygdala. Furthermore, OXT, but not LZP, enhanced the coupling between the cmA and the precuneus and dorsomedial prefrontal cortex. These data implicate inhibition of the cmA as a common denominator of anxiolytic action, with only OXT inducing large-scale connectivity changes of potential therapeutic relevance.